• 10X Genomics Inc TXG.OQ reported a quarterly adjusted loss of 40 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -41 cents. The mean expectation of nineteen analysts for the quarter was for a loss of 29 cents per share. Wall Street expected results to range from -38 cents to -14 cents per share.

• Revenue fell 10.3% to $165.02 million from a year ago; analysts expected $159.39 million.

• 10X Genomics Inc's reported EPS for the quarter was a loss of 40 cents​.

• The company reported a quarterly loss of $49.03 million.

• 10X Genomics Inc shares had fallen by 17.7% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 2.1% in the last three months.​

• In the last 30 days, three analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 10 "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for 10X Genomics Inc is $20.00

This summary was machine generated from LSEG data February 12 at 10:40 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)